Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model.
Fibrotic remodeling is a process common to chronic lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, acute respiratory distress syndrome and asthma. Based on preclinical studies phosphodiesterase 4 (PDE4) inhibitors may exhibit beneficial anti-inflammatory and a...
Main Authors: | Javier Milara, Esteban Morcillo, Daniel Monleon, Herman Tenor, Julio Cortijo |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4507994?pdf=render |
Similar Items
-
Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
by: Manuel Mata, et al.
Published: (2013-01-01) -
Downregulation of NOX4 Expression by Roflumilast N-Oxide Reduces Markers of Fibrosis in Lung Fibroblasts
by: Daniela Vecchio, et al.
Published: (2013-01-01) -
Mucins as a New Frontier in Pulmonary Fibrosis
by: Beatriz Ballester, et al.
Published: (2019-09-01) -
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
by: Beatriz Ballester, et al.
Published: (2019-01-01) -
Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
by: Koichiro Kamio, et al.
Published: (2018-04-01)